Estados Unidos - inglês - NLM (National Library of Medicine)

dr.reddys laboratories inc - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride capsules are indicated in the treatment of patients with wilson's disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. trientine hydrochloride and penicillamine cannot be considered interchangeable. trientine hydrochloride capsules should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.   unlike penicillamine, trientine hydrochloride capsules are not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment.   trienti

Estados Unidos - inglês - NLM (National Library of Medicine)

par pharmaceutical, inc. - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride capsules are indicated in the treatment of patients with wilson's disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride capsules is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. trientine hydrochloride capsules and penicillamine cannot be considered interchangeable. trientine hydrochloride capsules should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride capsules are not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride capsules was reported not to be effective in improving any clinical or biochemical parameter after 12 wee

Estados Unidos - inglês - NLM (National Library of Medicine)

kadmon pharmaceuticals, llc - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride is indicated in the treatment of patients with wilson’s disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. trientine hydrochloride and penicillamine cannot be considered interchangeable. trientine hydrochloride should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride is not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. trientine hydrochloride is not indicated f

Estados Unidos - inglês - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride is indicated in the treatment of patients with wilson's disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. trientine hydrochloride and penicillamine cannot be considered interchangeable. trientine hydrochloride should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride is not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. trientine hydrochloride is not indicated f

Estados Unidos - inglês - NLM (National Library of Medicine)

rising pharma holdings, inc. - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride is indicated in the treatment of patients with wilson's disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. trientine hydrochloride and penicillamine cannot be considered interchangeable. trientine hydrochloride should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride is not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. trientine hydrochloride is not indicated f

Estados Unidos - inglês - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride capsules are indicated in the treatment of patients with wilson’s disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride capsules are limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. trientine hydrochloride capsules and penicillamine cannot be considered interchangeable. trientine hydrochloride capsules should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride capsules are not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12

Israel - inglês - Ministry of Health

megapharm ltd - potassium sodium hydrogen citrate - granules - potassium sodium hydrogen citrate 2.427 g / 2.5 g - potassium citrate - to dissolve uric acid stones in the urinary tract. prevention of further stone formation.

Estados Unidos - inglês - NLM (National Library of Medicine)

recordati rare diseases - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 1 g in 1 g - cystadane ® is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are: - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and postmarketing experience with cystadane use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnanc

Estados Unidos - inglês - NLM (National Library of Medicine)

rare disease therapeutics, inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 6 g - cystadane® (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels.  included within the category of homocystinuria are:   - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. pregnancy category c: animal reproduction studies have not been conducted with cystadane.  it is also not known whether cystadane can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  cystadane should be given to a pregnant woman only if clearly needed. it is not known whether cystadane is excreted in human milk.  use only if clearly needed. the majority of case studies of homocystinuria patients treated with cystadane have been pediatric patients, including patients ranging in age from 24 days to 17 years [see clinical studies (14)].   children younger than 3 years of age may benefit

Estados Unidos - inglês - NLM (National Library of Medicine)

ropack inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 1 g in 1 g - cystadane ® (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. included within the category of homocystinuria are: - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. pregnancy category c: animal reproduction studies have not been conducted with cystadane. it is also not known whether cystadane can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  cystadane should be given to a pregnant woman only if clearly needed. it is not known whether cystadane is excreted in human milk. use only if clearly needed. the majority of case studies of homocystinuria patients treated with cystadane have been pediatric patients, including patients ranging in age from 24 days to 17 years [see clinical studies ( 14)]. children younger than 3 years of age may benefit from dose titration [see dosag